Adverum Biotechnologies (ADVM) Expected to Announce Earnings on Monday

Adverum Biotechnologies (NASDAQ:ADVM) is expected to be posting its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of ($1.80) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Friday, November 7, 2025 at 9:30 AM ET.

Adverum Biotechnologies (NASDAQ:ADVM) last posted its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($2.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.24) by ($0.10). On average, analysts expect Adverum Biotechnologies to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Adverum Biotechnologies Trading Down 2.6%

Shares of ADVM stock opened at $4.07 on Monday. The company has a market capitalization of $85.39 million, a P/E ratio of -0.52 and a beta of 0.98. The business’s 50 day moving average is $3.84 and its two-hundred day moving average is $3.05. Adverum Biotechnologies has a twelve month low of $1.78 and a twelve month high of $8.21.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ADVM. Chardan Capital reiterated a “buy” rating and issued a $33.00 price objective on shares of Adverum Biotechnologies in a research report on Wednesday, August 13th. Truist Financial set a $5.00 target price on shares of Adverum Biotechnologies in a research note on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Adverum Biotechnologies in a report on Tuesday, September 23rd. Royal Bank Of Canada raised shares of Adverum Biotechnologies to a “hold” rating in a report on Thursday, October 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adverum Biotechnologies in a research report on Friday. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Adverum Biotechnologies presently has a consensus rating of “Hold” and an average price target of $16.80.

Institutional Trading of Adverum Biotechnologies

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new stake in Adverum Biotechnologies during the second quarter worth about $153,000. Qube Research & Technologies Ltd purchased a new position in Adverum Biotechnologies in the second quarter valued at about $66,000. Marshall Wace LLP acquired a new stake in shares of Adverum Biotechnologies during the 2nd quarter valued at approximately $107,000. XTX Topco Ltd acquired a new stake in shares of Adverum Biotechnologies during the 2nd quarter valued at approximately $64,000. Finally, AQR Capital Management LLC purchased a new stake in shares of Adverum Biotechnologies during the 1st quarter worth approximately $148,000. Institutional investors and hedge funds own 48.17% of the company’s stock.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.